New York State Common Retirement Fund Acquires 66,402 Shares of InMode Ltd. $INMD

New York State Common Retirement Fund lifted its stake in shares of InMode Ltd. (NASDAQ:INMD) by 355.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 85,062 shares of the healthcare company’s stock after purchasing an additional 66,402 shares during the quarter. New York State Common Retirement Fund’s holdings in InMode were worth $1,267,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of INMD. Goldman Sachs Group Inc. grew its holdings in shares of InMode by 234.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company’s stock worth $19,935,000 after purchasing an additional 788,157 shares during the last quarter. Edgestream Partners L.P. acquired a new position in shares of InMode in the 2nd quarter worth approximately $8,294,000. Bank of America Corp DE lifted its holdings in InMode by 142.1% in the second quarter. Bank of America Corp DE now owns 862,209 shares of the healthcare company’s stock valued at $12,450,000 after buying an additional 506,134 shares during the period. Marshall Wace LLP grew its stake in InMode by 270.7% during the second quarter. Marshall Wace LLP now owns 555,573 shares of the healthcare company’s stock worth $8,022,000 after purchasing an additional 405,707 shares during the period. Finally, Lind Value II ApS bought a new position in shares of InMode during the 2nd quarter worth approximately $3,930,000. Institutional investors own 68.04% of the company’s stock.

InMode Trading Up 0.3%

INMD stock opened at $15.12 on Tuesday. The firm has a 50 day moving average of $14.66 and a 200-day moving average of $14.69. The firm has a market capitalization of $955.74 million, a P/E ratio of 7.00 and a beta of 2.19. InMode Ltd. has a 12 month low of $13.14 and a 12 month high of $19.78.

Wall Street Analyst Weigh In

INMD has been the topic of a number of research analyst reports. Canaccord Genuity Group set a $15.00 price objective on shares of InMode and gave the stock a “hold” rating in a research report on Wednesday, December 17th. BTIG Research reissued a “neutral” rating on shares of InMode in a research report on Monday, January 26th. Weiss Ratings reiterated a “sell (d+)” rating on shares of InMode in a research note on Thursday, January 22nd. Wall Street Zen lowered InMode from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, UBS Group decreased their price target on shares of InMode from $16.25 to $16.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $16.60.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.